BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Teiti I, Florie B, Pich C, Gence R, Lajoie-Mazenc I, Rochaix P, Favre G, Tilkin-Mariamé AF. In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression. Front Oncol 2015;5:156. [PMID: 26236689 DOI: 10.3389/fonc.2015.00156] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Keller L, Tardy C, Ligat L, Le Pennec S, Bery N, Koraïchi F, Chinestra P, David M, Gence R, Favre G, Cabantous S, Olichon A. Tripartite split-GFP assay to identify selective intracellular nanobody that suppresses GTPase RHOA subfamily downstream signaling. Front Immunol 2022;13:980539. [DOI: 10.3389/fimmu.2022.980539] [Reference Citation Analysis]
2 Zhang T, Jia Y, Yu Y, Zhang B, Xu F, Guo H. Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy. Adv Drug Deliv Rev 2022;186:114319. [PMID: 35545136 DOI: 10.1016/j.addr.2022.114319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Kim S, Kim SA, Han J, Kim IS. Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential. Int J Mol Sci 2021;22:12916. [PMID: 34884721 DOI: 10.3390/ijms222312916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Crosas-Molist E, Samain R, Kohlhammer L, Orgaz J, George S, Maiques O, Barcelo J, Sanz-Moreno V. RhoGTPase Signalling in Cancer Progression and Dissemination. Physiol Rev 2021. [PMID: 34541899 DOI: 10.1152/physrev.00045.2020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
5 de Sousa GR, Vieira GM, das Chagas PF, Pezuk JA, Brassesco MS. Should we keep rocking? Portraits from targeting Rho kinases in cancer. Pharmacol Res 2020;160:105093. [PMID: 32726671 DOI: 10.1016/j.phrs.2020.105093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Nam G, Yang Y, Kim I. Immunogenic clearance-mediated cancer vaccination. Biomaterials for Cancer Therapeutics 2020. [DOI: 10.1016/b978-0-08-102983-1.00020-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Jimbo H, Nagai H, Fujiwara S, Shimoura N, Nishigori C. Fas-FasL interaction in cytotoxic T cell-mediated vitiligo: The role of lesional expression of tumor necrosis factor-α and interferon-γ in Fas-mediated melanocyte apoptosis. Exp Dermatol 2020;29:61-70. [PMID: 31675451 DOI: 10.1111/exd.14053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
8 Yang Y, Nam GH, Kim GB, Kim YK, Kim IS. Intrinsic cancer vaccination. Adv Drug Deliv Rev 2019;151-152:2-22. [PMID: 31132376 DOI: 10.1016/j.addr.2019.05.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
9 Park SY, Kim IS. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy. Cancer Lett 2019;452:51-8. [PMID: 30910590 DOI: 10.1016/j.canlet.2019.03.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
10 Gökmen-polar Y. Roles of Rho/ROCK in Cancer Signaling. Predictive Biomarkers in Oncology 2019. [DOI: 10.1007/978-3-319-95228-4_15] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Nam GH, Lee EJ, Kim YK, Hong Y, Choi Y, Ryu MJ, Woo J, Cho Y, Ahn DJ, Yang Y, Kwon IC, Park SY, Kim IS. Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer. Nat Commun 2018;9:2165. [PMID: 29867097 DOI: 10.1038/s41467-018-04607-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 58] [Article Influence: 10.4] [Reference Citation Analysis]
12 Gandalovičová A, Rosel D, Fernandes M, Veselý P, Heneberg P, Čermák V, Petruželka L, Kumar S, Sanz-Moreno V, Brábek J. Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. Trends Cancer 2017;3:391-406. [PMID: 28670628 DOI: 10.1016/j.trecan.2017.04.008] [Cited by in Crossref: 181] [Cited by in F6Publishing: 156] [Article Influence: 36.2] [Reference Citation Analysis]
13 Thoppil RJ, Cappelli HC, Adapala RK, Kanugula AK, Paruchuri S, Thodeti CK. TRPV4 channels regulate tumor angiogenesis via modulation of Rho/Rho kinase pathway. Oncotarget 2016;7:25849-61. [PMID: 27029071 DOI: 10.18632/oncotarget.8405] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 9.5] [Reference Citation Analysis]
14 Millar FR, Janes SM, Giangreco A. Epithelial cell migration as a potential therapeutic target in early lung cancer. Eur Respir Rev 2017;26:160069. [PMID: 28143875 DOI: 10.1183/16000617.0069-2016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
15 Sarrabayrouse G, Pich C, Teiti I, Tilkin-Mariame AF. Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response. Int J Cancer 2017;140:747-55. [PMID: 27616679 DOI: 10.1002/ijc.30422] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
16 Chin VT, Nagrial AM, Chou A, Biankin AV, Gill AJ, Timpson P, Pajic M. Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Rev Mol Med 2015;17:e17. [PMID: 26507949 DOI: 10.1017/erm.2015.17] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]